Process Research and Impurity Control Strategy for Obeticholic Acid, a Farnesoid X Receptor Agonist

被引：4
|
作者：
Feng, Wei-Dong [1 ]
Zhuo, Song-Ming [2 ]
Zhang, Fu-Li [1 ,3 ]
机构：
[1] Zhejiang Univ Technol, Collaborat Innovat Ctr Yangtze River Delta Reg Gr, 18 Chaowang Rd, Hangzhou 310032, Zhejiang, Peoples R China
[2] China Pharmaceut Univ, Dept Pharmaceut Engn, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China
[3] China State Inst Pharmaceut Ind, Shanghai Inst Pharmaceut Ind, 285 Gebaini Rd, Shanghai 201203, Peoples R China
来源：
ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2019年 / 23卷 / 09期
关键词：
obeticholic acid; process; primary biliary cholangitis; nonalcoholic steatohepatitis;
D O I：
10.1021/acs.oprd.9b00252
中图分类号：
O69 [应用化学];
学科分类号：
081704 ;
摘要：
The process to obtain ICH-grade quality obeticholic acid (OCA) was improved, and the overall yield was 25.9%. The critical process parameters were established to reduce or avoid process-related impurities. The formation mechanisms, purge pathways, and control strategies for these impurities were also discussed for the first time. An high-performance liquid chromatography instrument utilizing the charged aerosol detection technique was applied for an impurity content assay in OCA for the first time. The developed process was robust and suitable for manufacturing scale-up.
引用
收藏
页码：1979 / 1989
页数：11
相关论文
共 50 条
  • [1] The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid
    Walters, J. R. F.
    Johnston, I. M.
    Nolan, J. D.
    Vassie, C.
    Pruzanski, M. E.
    Shapiro, D. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (01) : 54 - 64
  • [2] AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC
    Kowdley, K. V.
    Jones, D.
    Luketic, V.
    Chapman, R.
    Burroughs, A.
    Hirschfield, G.
    Poupon, R.
    Schramm, C.
    Vincent, C.
    Rust, C.
    Pares, A.
    Mason, A.
    Sciacca, C.
    Beecher-Jones, T.
    Bohm, O.
    Castelloe, E.
    Pruzanski, M.
    Shapiro, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S13 - S13
  • [3] Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis
    Ho, Peggy P.
    Steinman, Lawrence
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (06) : 1600 - 1605
  • [4] Synthesis of obeticholic acid, a farnesoid X receptor agonist, and its major metabolites labeled with deuterium
    Gai, Kuo
    Huang, Yu
    Liu, Baomin
    Zhang, Yinsheng
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2018, 61 (10): : 799 - 804
  • [5] Obeticholic Acid, a Farnesoid X Receptor Agonist, Reduces Bile Acid Synthesis in Patients With Primary Bile Acid Diarrhea
    Vassie, Claire
    Nolan, Jonathan D.
    Johnston, Ian M.
    Shapiro, David
    Walters, Julian R.
    GASTROENTEROLOGY, 2014, 146 (05) : S797 - S797
  • [6] Farnesoid X Receptor Agonist Obeticholic Acid Reduces Kidney Disease in a Mouse Model of Alport Syndrome
    Jones, Bryce A.
    Perry, Priscilla E.
    Davidson, Shania R.
    Santiago, Isabel Lopez
    Adapa, Sharmila
    Allen, Katherine C.
    Dial, Katelyn
    Rowland, Emma
    Myakala, Komuraiah
    Wang, Xiaoxin
    Levi, Moshe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 511 - 511
  • [7] Effect of the farnesoid X receptor agonist, obeticholic acid, in hepatocellular carcinoma: Is it NASH-dependent or -independent?
    Attia, Yasmeen
    Tawfiq, Rasha
    Adel, Aya
    Gibriel, Abdullah
    Hammam, Olfat
    Elmazar, Mohamed
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E520 - E520
  • [8] A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor
    Narayanan, Anila Kutty
    Surendran, Sudhindran
    Balakrishnan, Dinesh
    Gopalakrishnan, Unnikrishnan
    Malick, Shweta
    Valsan, Arun
    Philips, Abby Cyriac
    Watson, Christopher
    CURRENT REVIEWS IN CLINICAL AND EXPERIMENTAL PHARMACOLOGY, 2024, 19 (03) : 225 - 233
  • [9] Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
    Verbeke, Len
    Farre, Ricard
    Trebicka, Jonel
    Komuta, Mina
    Roskams, Tania
    Klein, Sabine
    Vander Elst, Ingrid
    Windmolders, Petra
    Vanuytsel, Tim
    Nevens, Frederik
    Laleman, Wim
    HEPATOLOGY, 2014, 59 (06) : 2286 - 2298
  • [10] The cancerogenic potential of primary human Cholangioracinoma cells is inhibited by Obeticholic Acid, a Farnesoid X Receptor (FXR) agonist
    Di Matteo, S.
    Nevi, L.
    Costantini, D.
    Colantonio, M.
    Giulitti, F.
    Napoletano, C.
    Safarikia, S.
    Manzi, E.
    Derose, A. M.
    Melandro, F.
    Bragazzi, M. C.
    Grazi, G.
    Berloco, P. B.
    Giuliante, F.
    Carpino, G.
    Cardinale, V.
    Gaudio, E.
    Alvaro, D.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 22 - 23
12345